These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
91 related articles for article (PubMed ID: 15384741)
1. COX-2 inhibition and cancer: experimental findings and clinical correlates. Roberts EG; Vona-Davis L; Riggs DR; Jackson BJ; Hohseni H; Kandzari SJ; McFadden DW W V Med J; 2004; 100(3):96-101. PubMed ID: 15384741 [TBL] [Abstract][Full Text] [Related]
2. Antiproliferative and apoptotic effects of rofecoxib on esophageal cancer in vitro(1). Vona-Davis L; Riggs DR; Jackson BJ; McFadden DW J Surg Res; 2004 Jun; 119(2):143-8. PubMed ID: 15145696 [TBL] [Abstract][Full Text] [Related]
3. COX-2 inhibition demonstrates potent anti-proliferative effects on bladder cancer in vitro. Mohseni H; Zaslau S; McFadden D; Riggs DR; Jackson BJ; Kandzari S J Surg Res; 2004 Jun; 119(2):138-42. PubMed ID: 15145695 [TBL] [Abstract][Full Text] [Related]
4. Celecoxib inhibits prostate cancer growth: evidence of a cyclooxygenase-2-independent mechanism. Patel MI; Subbaramaiah K; Du B; Chang M; Yang P; Newman RA; Cordon-Cardo C; Thaler HT; Dannenberg AJ Clin Cancer Res; 2005 Mar; 11(5):1999-2007. PubMed ID: 15756026 [TBL] [Abstract][Full Text] [Related]
5. Cyclooxygenase-2 inhibitor NS398 enhances antitumor effect of irradiation on hormone refractory human prostate carcinoma cells. Wen B; Deutsch E; Eschwege P; De Crevoisier R; Nasr E; Eschwege F; Bourhis J J Urol; 2003 Nov; 170(5):2036-9. PubMed ID: 14532848 [TBL] [Abstract][Full Text] [Related]
6. The cyclooxygenase 2-selective inhibitor NS398 inhibits proliferation of oral carcinoma cell lines by mechanisms dependent and independent of reduced prostaglandin E2 synthesis. Minter HA; Eveson JW; Huntley S; Elder DJ; Hague A Clin Cancer Res; 2003 May; 9(5):1885-97. PubMed ID: 12738747 [TBL] [Abstract][Full Text] [Related]
7. Effects of the selective COX-2 inhibitors celecoxib and rofecoxib on human vascular cells. Niederberger E; Manderscheid C; Grösch S; Schmidt H; Ehnert C; Geisslinger G Biochem Pharmacol; 2004 Jul; 68(2):341-50. PubMed ID: 15194006 [TBL] [Abstract][Full Text] [Related]
8. NS-398 inhibits tumor growth and liver metastasis of colon cancer through induction of apoptosis and suppression of the plasminogen activation system in a mouse model. Nishikawa M; Stapleton PP; Freeman TA; Gaughan JP; Matsuda T; Daly JM J Am Coll Surg; 2004 Sep; 199(3):428-35. PubMed ID: 15325613 [TBL] [Abstract][Full Text] [Related]
9. Inhibition of cyclooxygenase-2 with NS-398 and the prevention of radiation-induced transformation, micronuclei formation and clonogenic cell death in C3H 10T1/2 cells. Bisht KS; Bradbury CM; Zoberi I; Curry HA; Kaushal A; Roti Roti JL; Gius D Int J Radiat Biol; 2003 Nov; 79(11):879-88. PubMed ID: 14698956 [TBL] [Abstract][Full Text] [Related]
10. A selective cyclooxygenase-2 inhibitor, NS398, inhibits cell growth and induces cell cycle arrest in the G2/M phase in human esophageal squamous cell carcinoma cells. Kase S; Osaki M; Honjo S; Takeda A; Adachi K; Araki K; Ito H J Exp Clin Cancer Res; 2004 Jun; 23(2):301-7. PubMed ID: 15354416 [TBL] [Abstract][Full Text] [Related]
11. Synergistic effects of Cox-1 and -2 inhibition on bladder and prostate cancer in vitro. Farivar-Mohseni H; Kandzari SJ; Zaslau S; Riggs DR; Jackson BJ; McFadden DW Am J Surg; 2004 Nov; 188(5):505-10. PubMed ID: 15546559 [TBL] [Abstract][Full Text] [Related]
12. Mechanism of growth inhibitory effects of cyclooxygenase-2 inhibitor-NS398 on cancer cells. Li S; Tong Q; Zhang W; Wang Q; Chen Z; Wu Q Cancer Invest; 2008 May; 26(4):333-7. PubMed ID: 18443952 [TBL] [Abstract][Full Text] [Related]
13. Resistance of prostate cancer cell lines to COX-2 inhibitor treatment. Wagner M; Loos J; Weksler N; Gantner M; Corless CL; Barry JM; Beer TM; Garzotto M Biochem Biophys Res Commun; 2005 Jul; 332(3):800-7. PubMed ID: 15907789 [TBL] [Abstract][Full Text] [Related]
14. Effect of cyclooxygenase-2 (COX-2) inhibitors on prostate cancer cell proliferation. Srinath P; Rao PN; Knaus EE; Suresh MR Anticancer Res; 2003; 23(5A):3923-8. PubMed ID: 14666698 [TBL] [Abstract][Full Text] [Related]
15. Effects of nonsteroidal anti-inflammatory agents (NSAIDs) on ovarian carcinoma cell lines: preclinical evaluation of NSAIDs as chemopreventive agents. Rodríguez-Burford C; Barnes MN; Oelschlager DK; Myers RB; Talley LI; Partridge EE; Grizzle WE Clin Cancer Res; 2002 Jan; 8(1):202-9. PubMed ID: 11801560 [TBL] [Abstract][Full Text] [Related]
16. Inhibition of cyclooxygenase-2 activity by celecoxib does not lead to radiosensitization of human prostate cancer cells in vitro. Ohneseit PA; Krebiehl G; Dittmann K; Kehlbach R; Rodemann HP Radiother Oncol; 2007 Feb; 82(2):229-38. PubMed ID: 17207548 [TBL] [Abstract][Full Text] [Related]
17. Expression of cyclooxygenase-2 (COX-2) in human esophageal cancer and in vitro inhibition by a specific COX-2 inhibitor, NS-398. Yu HP; Shi LY; Lu WH; Su YH; Li YY; Xu SQ J Gastroenterol Hepatol; 2004 Jun; 19(6):638-42. PubMed ID: 15151617 [TBL] [Abstract][Full Text] [Related]
18. Synergistic tumoricidal effect between celecoxib and adenoviral-mediated delivery of mda-7 in human breast cancer cells. Suh YJ; Chada S; McKenzie T; Liu Y; Swisher SG; Lucci A; Hunt KK Surgery; 2005 Sep; 138(3):422-30. PubMed ID: 16213894 [TBL] [Abstract][Full Text] [Related]
19. The effects of cyclooxygenase-2 inhibitors on urological cancer cells. Yoshimura R; Matsuyama M; Kawahito Y; Takemoto Y; Tsuchida K; Kuratsukuri K; Segawa Y; Shinnka T; Sano H; Nakatani T Int J Mol Med; 2004 Jun; 13(6):789-93. PubMed ID: 15138613 [TBL] [Abstract][Full Text] [Related]
20. COX-2 correlates with F-box protein, Skp2 expression and prognosis in human gastric carcinoma. Honjo S; Kase S; Osaki M; Ardyanto TD; Kaibara N; Ito H Int J Oncol; 2005 Feb; 26(2):353-60. PubMed ID: 15645119 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]